Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

111.79
+1.281.16%
Pre-market: 111.790.00000.00%08:19 EDT
Volume:1.02M
Turnover:114.90M
Market Cap:9.30B
PE:-34.80
High:115.69
Open:110.74
Low:108.03
Close:110.51
52wk High:130.05
52wk Low:54.09
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.39
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.16
PE(LYR):-30.30

Loading ...

Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan

TIPRANKS
·
Sep 28

Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
Sep 24

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Kymera Therapeutics, Inc. : Stifel Raises Target Price to $152 from $132

THOMSON REUTERS
·
Sep 22

US Research Roundup-Boeing, Twilio, WP Carey

Reuters
·
Sep 22

Kymera Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Sep 16

Kymera Therapeutics Price Target Raised to $144.00/Share from $123.00 by B of a Securities

Dow Jones
·
Sep 15

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

MT Newswires Live
·
Sep 14

Wolfe upgrades Kymera Therapeutics to Outperform on potential upside

TIPRANKS
·
Sep 10

Kymera Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Sep 10

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
Sep 04

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 03

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT Newswires Live
·
Sep 02

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Sep 02

Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121

THOMSON REUTERS
·
Sep 02

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

THOMSON REUTERS
·
Sep 01

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewswire
·
Sep 01

Kymera Therapeutics Price Target Raised to $151.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Aug 27

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17